<DOC>
	<DOCNO>NCT00276679</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , temozolomide , work different way stop growth tumor cell , either kill cell stop dividing . PURPOSE : This phase II trial study well temozolomide work treat patient high-risk relapsed refractory neuroblastoma .</brief_summary>
	<brief_title>Temozolomide Treating Young Patients With High-Risk Relapsed Refractory Neuroblastoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine anti-tumor activity temozolomide young patient high-risk relapsed refractory neuroblastoma . Secondary - Determine duration response patient treated drug . - Determine tolerability drug patient - Determine tumor expression cellular repair mechanism repair DNA damage ( O6-methylguanine-DNA methyltransferase [ MGMT ] mismatch repair [ MMR ] system ) patient treat drug . - Correlate MGMT MMR expression outcomes patient treated drug . - Determine MGMT MMR expression/activity change tumor initial presentation , treatment , relapse/progression patient treat drug . - Determine activity MGMT bone marrow take relapse , term hematological toxicity , patient treat drug . OUTLINE : This multicenter , open label , nonrandomized study . Patients receive oral temozolomide daily 5 day . Treatment repeat every 28 day 2 course . Patients achieve stable respond disease completion 2 course may receive 10 additional course treatment absence disease progression unacceptable toxicity . PROJECTED ACCRUAL : A total 25 patient accrue study .</detailed_description>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven neuroblastoma Highrisk relapse refractory disease , define 1 following : Metastatic disease Localized MYCN amplify disease Localized non MYCN amplify disease second relapse Measurable primary metastatic disease crosssectional imaging MIBG scan PATIENT CHARACTERISTICS : Lansky performance status 40100 % Life expectancy &gt; 2 month Not pregnant nursing Fertile patient must use effective contraception course study 6 month study completion Organ toxicity &lt; grade 2 Platelets ≥ 100,000/mm^3 ( 50,000/mm^3 stem cell transplant case marrow involvement ) Neutrophil count ≥ 500/mm^3 Bilirubin &lt; 1.5 time normal AST ALT ≤ 2.5 time normal No known HIV positivity PRIOR CONCURRENT THERAPY : More 21 day since prior chemotherapy treatment ( isotretinoin count chemotherapy purpose ) More 30 day since prior radiotherapy except local palliative treatment pain control No 2 prior treatment neuroblastoma No concurrent investigative treatment neuroblastoma</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>January 2006</verification_date>
	<keyword>recurrent neuroblastoma</keyword>
	<keyword>disseminate neuroblastoma</keyword>
	<keyword>localize unresectable neuroblastoma</keyword>
</DOC>